Top

Published in:

Open Access 01-04-2021 | Solid Tumor | PHASE I STUDIES

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

Authors: Toshihiko Doi, Masaomi Tajimi, Joji Mori, Hiroya Asou, Koichi Inoue, Karim A. Benhadji, Yoichi Naito

Published in: Investigational New Drugs | Issue 2/2021

Summary

Background This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid tumors. Methods The study consisted of 2 dose levels of crenigacestat (25 mg and 50 mg), administered orally 3 times per week (TIW) over a 28-day cycle until disease progression, development of unacceptable toxicity, or any other discontinuation criteria were met. The primary objective was to evaluate the tolerability and determine the recommended dose of crenigacestat for Japanese patients. Secondary objectives were to characterize the safety and toxicity, the pharmacokinetic parameters, and to document any antitumor activity of crenigacestat. Results Eleven Japanese patients with advanced solid tumors were enrolled; 4 patients (median age of 64 years) received 25 mg of crenigacestat, and 7 patients (median age of 72 years) received 50 mg of crenigacestat. Median treatment duration was 8 weeks in the 25-mg treatment arm and 4 weeks in the 50-mg treatment arm. There were no dose-limiting toxicities or dose-limiting equivalent toxicities observed. None of the patients had a complete or partial response to the treatment. One patient (14.3%) with a desmoid tumor in the 50-mg treatment arm showed tumor size shrinkage of 22.4% and had stable disease for 22.5 months. Frequent (>14%) treatment-related-adverse events in both treatment arms included diarrhea, malaise, and vomiting. Conclusions Crenigacestat was tolerated in Japanese patients but with limited clinical activity. The recommended crenigacestat dose in Japanese patients is 50 mg TIW.

Trial registration: NCT02836600 (ClinicalTrials.gov) registered on July 19, 2016.

Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770–776. https://doi.org/10.1126/science.284.5415.770CrossRefPubMed

Mumm JS, Kopan R (2000) Notch signaling: from the outside in. Dev Biol 228:151–165. https://doi.org/10.1006/dbio.2000.9960CrossRefPubMed

Lai EC (2004) Notch signaling: control of cell communication and cell fate. Development 131:965–973. https://doi.org/10.1242/dev.01074CrossRefPubMed

Allenspach EJ, Maillard I, Aster JC, Pear WS (2002) Notch signaling in cancer. Cancer Biol Ther 1:466–476. https://doi.org/10.4161/cbt.1.5.159CrossRefPubMed

Radtke F, Raj K (2003) The role of notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3:756–767. https://doi.org/10.1038/nrc1186CrossRefPubMed

Li L, Tang P, Li S, Qin X, Yang H, Wu C et al (2017) Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy. Med Oncol 34:180. https://doi.org/10.1007/s12032-017-1039-6CrossRefPubMed

Koch U, Radtke F (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64:2746–2762. https://doi.org/10.1007/s00018-007-7164-1CrossRefPubMed

Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101–105. https://doi.org/10.1038/nature10113CrossRefPubMedPubMedCentral

Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D et al (2018) First-in-human study of LY3039478, an oral notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol 29:1911–1917. https://doi.org/10.1093/annonc/mdy244CrossRefPubMed

10.

Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C et al (2020) Safety and clinical activity of the notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Investig New Drugs 38:402–409. https://doi.org/10.1007/s10637-019-00739-xCrossRef

11.

Mir O, Azaro A, Merchan J, Chugh R, Trent J, Rodon J, Ohnmacht U et al (2018) Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. Eur J Cancer 103:88–97. https://doi.org/10.1016/j.ejca.2018.08.012CrossRefPubMed

12.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026CrossRefPubMed

13.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/JCO.2009.26.3541CrossRefPubMed

14.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 35:1773–1782. https://doi.org/10.1016/s0959-8049(99)00229-4CrossRefPubMed

15.

Kim H-A, Koo B-K, Cho J-H, Kim Y-Y, Seong J, Chang HJ et al (2012) Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest 122:3248–3259. https://doi.org/10.1172/JCI61216CrossRefPubMedPubMedCentral

16.

Kummar S, O'Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E et al (2017) Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol 35:1561–1569. https://doi.org/10.1200/JCO.2016.71.199417CrossRefPubMedPubMedCentral

17.

Shang H, Braggio D, Lee YJ, Al Sannaa GA, Creighton CJ, Bolshakov S et al (2015) Targeting the notch pathway: a potential therapeutic approach for desmoid tumors. Cancer 121:4088–4096. https://doi.org/10.1002/cncr.29564CrossRefPubMedPubMedCentral

18.

Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG et al (2012) Phase I study of RO4929097, a gamma secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30:2348–2353. https://doi.org/10.1200/JCO.2011.36.8282CrossRefPubMedPubMedCentral

19.

Tolcher AW, Chugh R, Chambers G, Thorpe V, Dupont J, Hill D et al (2012) A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors. J Clin Oncol 30(15_suppl):3025 https://doi.org/10.1200/jco.2012.30.15_suppl.3025CrossRef

20.

Takebe N, Nguyen D, Yang SX (2014) Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 141:140–149. https://doi.org/10.1016/j.pharmthera.2013.09.005CrossRefPubMed

21.

Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B et al (2015) A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin Cancer Res 21:60–67. https://doi.org/10.1158/1078-0432.CCR-14-0607CrossRefPubMed

22.

Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA et al (2016) A first-in-human phase I study of the oral notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer 56:1–9. https://doi.org/10.1016/j.ejca.2015.11.021CrossRefPubMed

23.

Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, Chen T, Zhu L, Poojary S, Basak S, Qi Z, Spreafico A, Fischer B, Desai J (2018) A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Investig New Drugs 36:1026–1036. https://doi.org/10.1007/s10637-018-0597-6CrossRef

Title: A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors
Authors: Toshihiko Doi
Masaomi Tajimi
Joji Mori
Hiroya Asou
Koichi Inoue
Karim A. Benhadji
Yoichi Naito
Publication date: 01-04-2021
Publisher: Springer US
Keyword: Solid Tumor
Published in: Investigational New Drugs / Issue 2/2021
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-020-01001-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2021

rAj-Tspin, a novel recombinant peptide from Apostichopus japonicus, suppresses the proliferation, migration, and invasion of BEL-7402 cells via a mechanism associated with the ITGB1-FAK-AKT pathway

Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Selective targeting of the androgen receptor-DNA binding domain by the novel antiandrogen SBF-1 and inhibition of the growth of prostate cancer cells

Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)

A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel

Keynote webinar | Spotlight on antibody–drug conjugates in cancer